{"protocolSection":{"identificationModule":{"nctId":"NCT02709746","orgStudyIdInfo":{"id":"12710A"},"secondaryIdInfos":[{"id":"2008-005354-20","type":"EUDRACT_NUMBER"},{"id":"2008","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2008"}],"organization":{"fullName":"H. Lundbeck A/S","class":"INDUSTRY"},"briefTitle":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)","officialTitle":"Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)"},"statusModule":{"statusVerifiedDate":"2020-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-05"},"primaryCompletionDateStruct":{"date":"2019-07-02","type":"ACTUAL"},"completionDateStruct":{"date":"2019-07-30","type":"ACTUAL"},"studyFirstSubmitDate":"2016-03-11","studyFirstSubmitQcDate":"2016-03-15","studyFirstPostDateStruct":{"date":"2016-03-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-05-26","resultsFirstSubmitQcDate":"2020-08-04","resultsFirstPostDateStruct":{"date":"2020-08-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-08-04","lastUpdatePostDateStruct":{"date":"2020-08-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"H. Lundbeck A/S","class":"INDUSTRY"},"collaborators":[{"name":"Takeda","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD)."},"conditionsModule":{"conditions":["Depressive Disorder, Major"],"keywords":["paediatric patients"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":784,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vortioxetine 10 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Vortioxetine 10 mg/day"]},{"label":"Vortioxetine 20 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Vortioxetine 20 mg/day"]},{"label":"Fluoxetine 20 mg/day,","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fluoxetine 20 mg/day"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"Vortioxetine 10 mg/day","description":"10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed","armGroupLabels":["Vortioxetine 10 mg/day"],"otherNames":["Brintellix ®","Lu AA21004"]},{"type":"DRUG","name":"Vortioxetine 20 mg/day","description":"20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed","armGroupLabels":["Vortioxetine 20 mg/day"],"otherNames":["Brintellix ®","Lu AA21004"]},{"type":"DRUG","name":"Fluoxetine 20 mg/day","description":"20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed","armGroupLabels":["Fluoxetine 20 mg/day,"]},{"type":"OTHER","name":"Placebo","description":"Encapsulated tablet","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","timeFrame":"From Randomization to Week 8"}],"secondaryOutcomes":[{"measure":"Change in CDRS-R Total Score During Treatment (at Week 2)","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.","timeFrame":"At week 2"},{"measure":"Change in CDRS-R Total Score During Treatment (at Week 4)","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","timeFrame":"At week 4"},{"measure":"Change in CDRS-R Total Score During Treatment (at Week 6)","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","timeFrame":"At week 6"},{"measure":"Change in CDRS-R Mood Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.","timeFrame":"From randomization to Week 8"},{"measure":"Change in CDRS-R Somatic Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in CDRS-R Subjective Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in CDRS-R Behaviour Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.","timeFrame":"From Randomization to Week 8"},{"measure":"CDRS-R Response","description":"Children Depression Rating Scale - Response: defined as a \\>= 50% decrease in CDRS-R total score, calculated as (change from baseline \\[Randomization\\])/(baseline value - 17).","timeFrame":"From Randomization to Week 8"},{"measure":"CDRS-R Remission","description":"Remission is defined as a CDRS-R total score \\<= 28.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents","description":"Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.","timeFrame":"From randomization to week 8"},{"measure":"Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child","description":"The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.","timeFrame":"From randomization to Week 8"},{"measure":"Parent Global Assessment-Global Improvement (PGA) Score","description":"The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).","timeFrame":"From Randomization to Week 8"},{"measure":"Change in Symbol Digit Modalities Test (SDMT)","description":"The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).","timeFrame":"From Randomization to Week 8"},{"measure":"Change in Clinical Global Impression Severity of Illness (CGI-S) Score","description":"The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).","timeFrame":"From Randomization to Week 8"},{"measure":"Clinical Global Impression - Global Improvement (CGI-I) Score","description":"The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.","timeFrame":"From Randomization to Week 8"},{"measure":"CGI-S Remission","description":"Remission defined as CGI-S score of 1 or 2.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in Children's Global Assessment Scale (CGAS) Score","description":"The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in PedsQL VAS: Sad or Blue (Sadness) Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in PedsQL VAS: Angry Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in PedsQL VAS: Worry Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in PedsQL VAS: Tired (Fatigue) Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","timeFrame":"From Randomization to week 8"},{"measure":"Change in PedsQL VAS: Pain or Hurt Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in PedsQL VAS Total Average Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.","timeFrame":"From Randomization to week 8"},{"measure":"Change in PedsQL Emotional Distress Summary Average Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.","timeFrame":"From Randomization to week 8"},{"measure":"Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores","description":"PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.","timeFrame":"From Randomization to Week 8"},{"measure":"Change in PQ-LES-Q Overall Score","description":"PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).","timeFrame":"From Randomization to Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient is a male or female, aged ≥12 and ≤17 years at Screening (patients who turn 18 years during the study will be allowed to continue in the study).\n* The patient has Major depressive disorder (MDD), diagnosed according to DSM-5™.\n* The patient has a Children Depression Rating Scale - Revised (CDRS-R) total score ≥45 at the Screening Visit and at the Baseline.\n* The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≥4 at the Screening Visit and at the Baseline\n* The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patient has participated in a clinical study \\<30 days prior to the Screening Visit.\n\nOther protocol defined inclusion and exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Email contact via H. Lundbeck A/S","affiliation":"LundbeckClinicalTrials@Lundbeck.com","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"US1369","city":"Dothan","state":"Alabama","country":"United States","geoPoint":{"lat":31.22323,"lon":-85.39049}},{"facility":"US1333","city":"Tucson","state":"Arizona","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"US1310","city":"Little Rock","state":"Arkansas","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"US1062","city":"Costa Mesa","state":"California","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"US1387","city":"Downey","state":"California","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"US1114","city":"Escondido","state":"California","country":"United States","geoPoint":{"lat":33.11921,"lon":-117.08642}},{"facility":"US1118","city":"Glendale","state":"California","country":"United States","geoPoint":{"lat":34.14251,"lon":-118.25508}},{"facility":"US1123","city":"Imperial","state":"California","country":"United States","geoPoint":{"lat":32.84755,"lon":-115.56944}},{"facility":"US1160 Renew Behavioral Health, Inc.","city":"Long Beach","state":"California","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"US1368","city":"Orange","state":"California","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"US1370","city":"Panorama City","state":"California","country":"United States","geoPoint":{"lat":34.22473,"lon":-118.44981}},{"facility":"US1351","city":"Wildomar","state":"California","country":"United States","geoPoint":{"lat":33.59891,"lon":-117.28004}},{"facility":"US1133","city":"Washington D.C.","state":"District of Columbia","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"US1217","city":"Gainesville","state":"Florida","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"US1229","city":"Orange City","state":"Florida","country":"United States","geoPoint":{"lat":28.94888,"lon":-81.29867}},{"facility":"US1009","city":"Atlanta","state":"Georgia","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"US1313","city":"Marietta","state":"Georgia","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"US1311","city":"Naperville","state":"Illinois","country":"United States","geoPoint":{"lat":41.78586,"lon":-88.14729}},{"facility":"US1315","city":"Naperville","state":"Illinois","country":"United States","geoPoint":{"lat":41.78586,"lon":-88.14729}},{"facility":"US1103","city":"Oak Brook","state":"Illinois","country":"United States","geoPoint":{"lat":41.83281,"lon":-87.92895}},{"facility":"US1386","city":"Wichita","state":"Kansas","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"US1261","city":"Lake Charles","state":"Louisiana","country":"United States","geoPoint":{"lat":30.21309,"lon":-93.2044}},{"facility":"US1015","city":"Baltimore","state":"Maryland","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"US1385 Ericksen Research And Development","city":"Clinton","state":"Mississippi","country":"United States","geoPoint":{"lat":32.34153,"lon":-90.32176}},{"facility":"US1064","city":"Creve Coeur","state":"Missouri","country":"United States","geoPoint":{"lat":38.66089,"lon":-90.42262}},{"facility":"US1314","city":"O'Fallon","state":"Missouri","country":"United States","geoPoint":{"lat":38.81061,"lon":-90.69985}},{"facility":"US1266","city":"Saint Charles","state":"Missouri","country":"United States","geoPoint":{"lat":38.78394,"lon":-90.48123}},{"facility":"US1312","city":"Berlin","state":"New Jersey","country":"United States","geoPoint":{"lat":39.79123,"lon":-74.92905}},{"facility":"US1222","city":"Princeton","state":"New Jersey","country":"United States","geoPoint":{"lat":40.34872,"lon":-74.65905}},{"facility":"US1317","city":"New York","state":"New York","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"US1171","city":"Rochester","state":"New York","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"US1190","city":"Staten Island","state":"New York","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"US1051","city":"Cincinnati","state":"Ohio","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"US1054","city":"Cleveland","state":"Ohio","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"US1334","city":"Middleburg Heights","state":"Ohio","country":"United States","geoPoint":{"lat":41.36144,"lon":-81.81291}},{"facility":"US1323","city":"Oklahoma City","state":"Oklahoma","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"US1329","city":"Oklahoma City","state":"Oklahoma","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"US1328","city":"Austin","state":"Texas","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"US1320","city":"Plano","state":"Texas","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"US1162","city":"San Antonio","state":"Texas","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"US1308","city":"Orem","state":"Utah","country":"United States","geoPoint":{"lat":40.2969,"lon":-111.69465}},{"facility":"US1309","city":"Richmond","state":"Virginia","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"BG1023","city":"Targovishte","country":"Bulgaria","geoPoint":{"lat":43.2512,"lon":26.57215}},{"facility":"BG1025","city":"Varna","country":"Bulgaria","geoPoint":{"lat":43.21912,"lon":27.91024}},{"facility":"CA1036 University of Calgary","city":"Calgary","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"CA1038","city":"Toronto","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"CO1003","city":"Barranquilla","country":"Colombia","geoPoint":{"lat":10.96854,"lon":-74.78132}},{"facility":"CO1001","city":"Bello","country":"Colombia","geoPoint":{"lat":6.33732,"lon":-75.55795}},{"facility":"CO1004","city":"Bogotá","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"CO1002","city":"Pereira","country":"Colombia","geoPoint":{"lat":4.81428,"lon":-75.69488}},{"facility":"EE1007","city":"Tallinn","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"EE1015","city":"Viljandi","country":"Estonia","geoPoint":{"lat":58.36319,"lon":25.59159}},{"facility":"FR1041","city":"Douai","country":"France","geoPoint":{"lat":50.37069,"lon":3.07922}},{"facility":"FR1017","city":"Élancourt","country":"France","geoPoint":{"lat":48.78421,"lon":1.9552}},{"facility":"FR1009","city":"Nantes","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"DE1078","city":"Freiburg im Breisgau","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"DE1034","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"DE1077","city":"Mannheim","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"DE1081","city":"Maulbronn","country":"Germany","geoPoint":{"lat":48.99958,"lon":8.80337}},{"facility":"DE1076","city":"Tübingen","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"HU1023","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"HU1020","city":"Gyula","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"IT1075","city":"Cagliari","country":"Italy","geoPoint":{"lat":39.23054,"lon":9.11917}},{"facility":"IT1073","city":"Genova","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"IT1029","city":"Messina","country":"Italy","geoPoint":{"lat":38.19394,"lon":15.55256}},{"facility":"IT1068","city":"Naples","country":"Italy","geoPoint":{"lat":40.85216,"lon":14.26811}},{"facility":"IT1074","city":"Padova","country":"Italy","geoPoint":{"lat":44.38225,"lon":11.14261}},{"facility":"IT1070","city":"Pisa","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"IT1072 Osppedale Bambin gesu","city":"Rome","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"LV1002","city":"Jelgava","country":"Latvia","geoPoint":{"lat":56.65,"lon":23.71278}},{"facility":"LV1008","city":"Liepāja","country":"Latvia","geoPoint":{"lat":56.50474,"lon":21.01085}},{"facility":"LV1009","city":"Riga","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"LV1007","city":"Sigulda","country":"Latvia","geoPoint":{"lat":57.15375,"lon":24.85953}},{"facility":"MX1014","city":"Culiacán","country":"Mexico","geoPoint":{"lat":24.80209,"lon":-107.39421}},{"facility":"MX1011","city":"Guadalajara","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"MX1013","city":"Guadalajara","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"MX1022","city":"Guadalajara","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"MX1023","city":"Mazatlán","country":"Mexico","geoPoint":{"lat":23.22163,"lon":-106.41885}},{"facility":"MX1003","city":"Mexico City","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"MX1001","city":"Nuevo León","country":"Mexico","geoPoint":{"lat":32.4095,"lon":-115.18896}},{"facility":"PL1002","city":"Bialystok","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"PL1050","city":"Gdansk","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"PL1068","city":"Kielce","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"PL1057","city":"Lublin","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"PL1052","city":"Poznan","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"PL1054","city":"Wąbrzeźno","country":"Poland","geoPoint":{"lat":53.27989,"lon":18.94773}},{"facility":"PL1051","city":"Wroclaw","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"RU1009","city":"Arkhangelsk","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"RU1059","city":"Engel's","country":"Russia","geoPoint":{"lat":51.48389,"lon":46.10528}},{"facility":"RU1046","city":"Krasnodar","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"facility":"RU1011","city":"Lipetsk","country":"Russia","geoPoint":{"lat":52.5876,"lon":39.55151}},{"facility":"RU1004","city":"Nizhny Novgorod","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"RU1010","city":"Novosibirsk","country":"Russia","geoPoint":{"lat":55.02259,"lon":82.93175}},{"facility":"RU1012","city":"Rostov-on-Don","country":"Russia","geoPoint":{"lat":47.21997,"lon":39.70769}},{"facility":"RU1044","city":"Rostov-on-Don","country":"Russia","geoPoint":{"lat":47.21997,"lon":39.70769}},{"facility":"RU1030","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"RU1013","city":"Saratov","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"RU1038","city":"Saratov","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"RU1057","city":"Tomsk","country":"Russia","geoPoint":{"lat":56.50049,"lon":84.98216}},{"facility":"RU1048","city":"Tonnel’nyy","country":"Russia","geoPoint":{"lat":45.6102,"lon":40.325}},{"facility":"RU1016","city":"Yekaterinburg","country":"Russia","geoPoint":{"lat":56.85733,"lon":60.61529}},{"facility":"RS1006 Clinic of Neurology and Psychiatry for Children and Adolescents","city":"Belgrade","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"RS1010","city":"Belgrade","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"RS1011","city":"Kragujevac","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"RS1003","city":"Niš","country":"Serbia","geoPoint":{"lat":43.32472,"lon":21.90333}},{"facility":"RS1007","city":"Novi Sad","country":"Serbia","geoPoint":{"lat":45.25167,"lon":19.83694}},{"facility":"ZA1019","city":"Cape Town","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"ZA1022","city":"Randburg","country":"South Africa","geoPoint":{"lat":-26.0941,"lon":28.00123}},{"facility":"ZA1023","city":"Sandton","country":"South Africa","geoPoint":{"lat":-26.104,"lon":28.054}},{"facility":"KR1035","city":"Cheonan","country":"South Korea","geoPoint":{"lat":36.8065,"lon":127.1522}},{"facility":"UA1037","city":"Gyeongsang","country":"South Korea","geoPoint":{"lat":35.3164,"lon":126.93455}},{"facility":"KR1032","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"KR1038","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"ES1041","city":"Alcorcón","country":"Spain","geoPoint":{"lat":40.34582,"lon":-3.82487}},{"facility":"ES1044","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"ES1043","city":"Pamplona","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"ES1018 Hospital de Sabadell","city":"Sabadell","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"ES1040","city":"Torremolinos","country":"Spain","geoPoint":{"lat":36.62035,"lon":-4.49976}},{"facility":"UA1002","city":"Kyiv","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"UA1019","city":"Odesa","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"UA1001","city":"Poltava","country":"Ukraine","geoPoint":{"lat":49.58925,"lon":34.55367}},{"facility":"UA1004","city":"Ternopil","country":"Ukraine","geoPoint":{"lat":49.55404,"lon":25.59067}},{"facility":"GB1051","city":"Glasgow","country":"United Kingdom","geoPoint":{"lat":55.86515,"lon":-4.25763}},{"facility":"GB1047","city":"Liverpool","country":"United Kingdom","geoPoint":{"lat":53.41058,"lon":-2.97794}}]},"referencesModule":{"references":[{"pmid":"35033635","type":"DERIVED","citation":"Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1106-1118.e2. doi: 10.1016/j.jaac.2022.01.004. Epub 2022 Jan 13."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Patients who did not fulfil the randomization criteria for the Double-blind treatment (DBT) Period, were withdrawn from the study after the Single-blind treatment (SBT) period. Patients who fulfilled the randomization criteria for the DBT Period, continued into the DBT Period.","groups":[{"id":"FG000","title":"Single-blind Treatment, Placebo","description":"Placebo, encapsulated, orally"},{"id":"FG001","title":"DBT, Vortioxetine 10 mg","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"FG002","title":"DBT, Vortioxetine 20 mg","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"FG003","title":"DBT, Fluoxetine 20 mg","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"FG004","title":"DBT, Placebo","description":"Placebo, encapsulated, orally"}],"periods":[{"title":"Phase A (Single-blind Treatment Period)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"784"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"616"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"168"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Not sepcified","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Non-compliance with study drug","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Enrolled not treated","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Do not fulfill rand criteria for DBT","reasons":[{"groupId":"FG000","numSubjects":"103"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}]},{"title":"Phase B (Double-blind Treatment Period)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"147"},{"groupId":"FG002","numSubjects":"162"},{"groupId":"FG003","numSubjects":"153"},{"groupId":"FG004","numSubjects":"154"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"126"},{"groupId":"FG002","numSubjects":"140"},{"groupId":"FG003","numSubjects":"138"},{"groupId":"FG004","numSubjects":"138"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"22"},{"groupId":"FG003","numSubjects":"15"},{"groupId":"FG004","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"7"}]},{"type":"Non-compliance with study drug","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"enrolled not treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Single-blind Treatment (SBT), Placebo","description":"Single-blind treatment, Placebo (encapsulated, orally) and Brief Psychosocial Intervention (BPI) for 4 weeks"},{"id":"BG001","title":"DBT, Vortioxetine 10 mg","description":"Eligible patients from SBT period (patients with incomplete improvement), will be randomly assigned (1:1:1:1) double-blind treatment in DBT Period, 8 weeks.\n\nVortioxetine 10 mg/day, encapsulated tablets, orally."},{"id":"BG002","title":"DBT, Vortioxetine 20 mg","description":"Eligible patients from SBT period (patients with incomplete improvement), will be randomly assigned (1:1:1:1) double-blind treatment in DBT Period, 8 weeks.\n\nVortioxetine 20 mg/day, encapsulated tablets, orally."},{"id":"BG003","title":"DBT, Fluoxetine 20 mg","description":"Eligible patients from SBT period (patients with incomplete improvement), will be randomly assigned (1:1:1:1) double-blind treatment in DBT Period, 8 weeks.\n\nFluoxetine 20 mg/day, encapsulated tablets, orally."},{"id":"BG004","title":"DBT, Placebo","description":"Eligible patients from SBT period (patients with incomplete improvement), will be randomly assigned (1:1:1:1) double-blind treatment in DBT Period, 8 weeks.\n\nPlacebo, encapsulated tablets, orally."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"147"},{"groupId":"BG002","value":"162"},{"groupId":"BG003","value":"153"},{"groupId":"BG004","value":"154"},{"groupId":"BG005","value":"784"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14.7","spread":"1.61"},{"groupId":"BG001","value":"14.8","spread":"1.66"},{"groupId":"BG002","value":"14.5","spread":"1.63"},{"groupId":"BG003","value":"14.8","spread":"1.60"},{"groupId":"BG004","value":"14.6","spread":"1.60"},{"groupId":"BG005","value":"14.67","spread":"1.62"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"97"},{"groupId":"BG003","value":"103"},{"groupId":"BG004","value":"105"},{"groupId":"BG005","value":"509"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"49"},{"groupId":"BG005","value":"275"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"13"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"117"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"110"},{"groupId":"BG003","value":"112"},{"groupId":"BG004","value":"106"},{"groupId":"BG005","value":"544"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"21"},{"groupId":"BG005","value":"95"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"14"}]}]}]},{"title":"CDRS-R total score at Enrolment","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.24","spread":"10.00"},{"groupId":"BG001","value":"64.82","spread":"9.38"},{"groupId":"BG002","value":"65.29","spread":"9.73"},{"groupId":"BG003","value":"64.06","spread":"8.65"},{"groupId":"BG004","value":"64.02","spread":"8.96"},{"groupId":"BG005","value":"63.85","spread":"9.46"}]}]}]},{"title":"CGI-S at Enrolment","description":"The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.82","spread":"0.68"},{"groupId":"BG001","value":"4.99","spread":"0.77"},{"groupId":"BG002","value":"5.00","spread":"0.71"},{"groupId":"BG003","value":"4.97","spread":"0.68"},{"groupId":"BG004","value":"4.92","spread":"0.69"},{"groupId":"BG005","value":"4.94","spread":"0.71"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","populationDescription":"Double-blind treatment period","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"},{"id":"OG004","title":"Vortioxetine Average (Avg. VOR)","description":"patients are randomized to one of four treatments.\n\nAvg.- VOR is a calculation based on the treatment estimates from VOR 10 mg and VOR 20 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"},{"groupId":"OG004","value":"265"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.09","spread":"1.27"},{"groupId":"OG001","value":"-18.94","spread":"1.22"},{"groupId":"OG002","value":"-21.95","spread":"1.23"},{"groupId":"OG003","value":"-18.22","spread":"1.22"},{"groupId":"OG004","value":"-18.01","spread":"0.98"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4702","statisticalMethod":"Mixed Model Repeated Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.94","ciUpperLimit":"4.2"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6373","statisticalMethod":"Mixed Model Repeated Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.71","ciUpperLimit":"2.27"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0152","statisticalMethod":"Mixed Model Repeated Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-3.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.74","ciUpperLimit":"-0.72"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8778","statisticalMethod":"Mixed Model Repeated Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.41","ciUpperLimit":"2.82"}]},{"type":"SECONDARY","title":"Change in CDRS-R Total Score During Treatment (at Week 2)","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"At week 2","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"150"},{"groupId":"OG003","value":"153"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.58","spread":"1.02"},{"groupId":"OG001","value":"-10.15","spread":"0.99"},{"groupId":"OG002","value":"-10.34","spread":"1.00"},{"groupId":"OG003","value":"-8.83","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Change in CDRS-R Total Score During Treatment (at Week 4)","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"At week 4","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"145"},{"groupId":"OG003","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.32","spread":"1.14"},{"groupId":"OG001","value":"-15.03","spread":"1.10"},{"groupId":"OG002","value":"-16.25","spread":"1.11"},{"groupId":"OG003","value":"-13.71","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Change in CDRS-R Total Score During Treatment (at Week 6)","description":"The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"At week 6","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"145"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"142"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.43","spread":"1.24"},{"groupId":"OG001","value":"-17.78","spread":"1.19"},{"groupId":"OG002","value":"-19.20","spread":"1.2"},{"groupId":"OG003","value":"-16.71","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Change in CDRS-R Mood Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.05","spread":"0.40"},{"groupId":"OG001","value":"-5.47","spread":"0.38"},{"groupId":"OG002","value":"-6.53","spread":"0.38"},{"groupId":"OG003","value":"-5.32","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Change in CDRS-R Somatic Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.63","spread":"0.46"},{"groupId":"OG001","value":"-6.03","spread":"0.44"},{"groupId":"OG002","value":"-6.79","spread":"0.45"},{"groupId":"OG003","value":"-5.78","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Change in CDRS-R Subjective Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"0.22"},{"groupId":"OG001","value":"-2.63","spread":"0.21"},{"groupId":"OG002","value":"-3.23","spread":"0.21"},{"groupId":"OG003","value":"-2.66","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in CDRS-R Behaviour Score","description":"Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.32","spread":"0.38"},{"groupId":"OG001","value":"-4.90","spread":"0.36"},{"groupId":"OG002","value":"-5.52","spread":"0.37"},{"groupId":"OG003","value":"-4.73","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Response","description":"Children Depression Rating Scale - Response: defined as a \\>= 50% decrease in CDRS-R total score, calculated as (change from baseline \\[Randomization\\])/(baseline value - 17).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"49"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Remission","description":"Remission is defined as a CDRS-R total score \\<= 28.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"20"}]}]}]},{"type":"SECONDARY","title":"Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents","description":"Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"From randomization to week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.23","spread":"0.56"},{"groupId":"OG001","value":"-6.48","spread":"0.54"},{"groupId":"OG002","value":"-8.00","spread":"0.54"},{"groupId":"OG003","value":"-6.62","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child","description":"The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.48","spread":"0.61"},{"groupId":"OG001","value":"-5.55","spread":"0.59"},{"groupId":"OG002","value":"-6.30","spread":"0.59"},{"groupId":"OG003","value":"-6.03","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Parent Global Assessment-Global Improvement (PGA) Score","description":"The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"0.10"},{"groupId":"OG001","value":"2.74","spread":"0.09"},{"groupId":"OG002","value":"2.49","spread":"0.09"},{"groupId":"OG003","value":"2.72","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change in Symbol Digit Modalities Test (SDMT)","description":"The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"1.02"},{"groupId":"OG001","value":"2.64","spread":"0.98"},{"groupId":"OG002","value":"2.69","spread":"0.98"},{"groupId":"OG003","value":"2.41","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression Severity of Illness (CGI-S) Score","description":"The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.10"},{"groupId":"OG001","value":"-1.38","spread":"0.10"},{"groupId":"OG002","value":"-1.59","spread":"0.10"},{"groupId":"OG003","value":"-1.21","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression - Global Improvement (CGI-I) Score","description":"The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"0.10"},{"groupId":"OG001","value":"2.69","spread":"0.09"},{"groupId":"OG002","value":"2.50","spread":"0.09"},{"groupId":"OG003","value":"2.73","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"CGI-S Remission","description":"Remission defined as CGI-S score of 1 or 2.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"24"}]}]}]},{"type":"SECONDARY","title":"Change in Children's Global Assessment Scale (CGAS) Score","description":"The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.24","spread":"1.25"},{"groupId":"OG001","value":"13.89","spread":"1.20"},{"groupId":"OG002","value":"16.43","spread":"1.20"},{"groupId":"OG003","value":"14.52","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.19"},{"groupId":"OG001","value":"-0.76","spread":"0.18"},{"groupId":"OG002","value":"-0.78","spread":"0.18"},{"groupId":"OG003","value":"-0.71","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL VAS: Sad or Blue (Sadness) Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.90","spread":"0.26"},{"groupId":"OG001","value":"-1.71","spread":"0.25"},{"groupId":"OG002","value":"-2.45","spread":"0.25"},{"groupId":"OG003","value":"-2.12","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL VAS: Angry Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.23"},{"groupId":"OG001","value":"-0.70","spread":"0.23"},{"groupId":"OG002","value":"-1.01","spread":"0.23"},{"groupId":"OG003","value":"-0.59","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL VAS: Worry Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.25"},{"groupId":"OG001","value":"-1.17","spread":"0.24"},{"groupId":"OG002","value":"-0.91","spread":"0.24"},{"groupId":"OG003","value":"-1.33","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL VAS: Tired (Fatigue) Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"0.29"},{"groupId":"OG001","value":"-1.40","spread":"0.28"},{"groupId":"OG002","value":"-1.55","spread":"0.28"},{"groupId":"OG003","value":"-1.27","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL VAS: Pain or Hurt Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"0.22"},{"groupId":"OG001","value":"-0.97","spread":"0.21"},{"groupId":"OG002","value":"-0.83","spread":"0.21"},{"groupId":"OG003","value":"-0.76","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL VAS Total Average Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.17"},{"groupId":"OG001","value":"-1.13","spread":"0.16"},{"groupId":"OG002","value":"-1.33","spread":"0.16"},{"groupId":"OG003","value":"-1.14","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in PedsQL Emotional Distress Summary Average Score","description":"The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"0.18"},{"groupId":"OG001","value":"-1.09","spread":"0.17"},{"groupId":"OG002","value":"-1.33","spread":"0.17"},{"groupId":"OG003","value":"-1.18","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores","description":"PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.62","spread":"0.97"},{"groupId":"OG001","value":"7.56","spread":"0.93"},{"groupId":"OG002","value":"9.26","spread":"0.94"},{"groupId":"OG003","value":"7.06","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change in PQ-LES-Q Overall Score","description":"PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).","populationDescription":"Double-blind treatment period. There where overall numbers of participants analyzed are not consistent with numbers provided in the participant flow can be due to particpant flow module total number of patients also includes patients that were enrolled but not treated and other reasons of discontinuation from the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Randomization to Week 8","groups":[{"id":"OG000","title":"Vortioxetine 10 mg/Day","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG001","title":"Vortioxetine 20 mg/Day","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"},{"id":"OG002","title":"Fluoxetine 20 mg/Day,","description":"Fluoxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"},{"id":"OG003","title":"Placebo","description":"Placebo: Encapsulated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.08"},{"groupId":"OG001","value":"0.43","spread":"0.08"},{"groupId":"OG002","value":"0.67","spread":"0.08"},{"groupId":"OG003","value":"0.51","spread":"0.08"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"16 weeks","description":"There where the total numbers of participants at risk are not onsistent with numbers provided in the particpant flow module is due that patients that were enrolled but not treated are included in the total number in the participant flow module.","eventGroups":[{"id":"EG000","title":"SBT, Placebo","description":"Patients not randomized to DBT period","deathsNumAffected":0,"deathsNumAtRisk":777,"seriousNumAffected":13,"seriousNumAtRisk":777,"otherNumAffected":128,"otherNumAtRisk":777},{"id":"EG001","title":"DBT, Vortioxetine 10 mg","description":"Vortioxetine 10 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed","deathsNumAffected":0,"deathsNumAtRisk":147,"seriousNumAffected":4,"seriousNumAtRisk":147,"otherNumAffected":47,"otherNumAtRisk":147},{"id":"EG002","title":"DBT, Vortioxetine 20 mg","description":"Vortioxetine 20 mg/day: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed","deathsNumAffected":0,"deathsNumAtRisk":161,"seriousNumAffected":7,"seriousNumAtRisk":161,"otherNumAffected":57,"otherNumAtRisk":161},{"id":"EG003","title":"DBT, Fluoxetine 20 mg","description":"Vortioxetine 20 mg/day: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed","deathsNumAffected":0,"deathsNumAtRisk":153,"seriousNumAffected":3,"seriousNumAtRisk":153,"otherNumAffected":40,"otherNumAtRisk":153},{"id":"EG004","title":"DBT, Placebo","description":"Placebo, encapsulated tablet, orally","deathsNumAffected":0,"deathsNumAtRisk":154,"seriousNumAffected":1,"seriousNumAtRisk":154,"otherNumAffected":30,"otherNumAtRisk":154}],"seriousEvents":[{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":777},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Gastrointestinal viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":154}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Generalised anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Suicidal behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":777},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":147},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":161},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":777},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":147},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":153},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":154}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":777},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":147},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":161},{"groupId":"EG003","numEvents":11,"numAffected":7,"numAtRisk":153},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":154}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":28,"numAtRisk":777},{"groupId":"EG001","numEvents":23,"numAffected":21,"numAtRisk":147},{"groupId":"EG002","numEvents":48,"numAffected":31,"numAtRisk":161},{"groupId":"EG003","numEvents":16,"numAffected":10,"numAtRisk":153},{"groupId":"EG004","numEvents":9,"numAffected":7,"numAtRisk":154}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":777},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":147},{"groupId":"EG002","numEvents":20,"numAffected":15,"numAtRisk":161},{"groupId":"EG003","numEvents":10,"numAffected":8,"numAtRisk":153},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":154}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":26,"numAtRisk":777},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":147},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":161},{"groupId":"EG003","numEvents":12,"numAffected":10,"numAtRisk":153},{"groupId":"EG004","numEvents":7,"numAffected":5,"numAtRisk":154}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":21,"numAtRisk":777},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":147},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":161},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":153},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":154}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MEDDRA - 21.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":65,"numAtRisk":777},{"groupId":"EG001","numEvents":37,"numAffected":23,"numAtRisk":147},{"groupId":"EG002","numEvents":46,"numAffected":20,"numAtRisk":161},{"groupId":"EG003","numEvents":16,"numAffected":10,"numAtRisk":153},{"groupId":"EG004","numEvents":19,"numAffected":12,"numAtRisk":154}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Email contact via","organization":"H. Lundbeck A/S","email":"LundbeckClinicalTrials@Lundbeck.com","phone":"+45 36301311"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-07-05","uploadDate":"2020-02-10T07:25","filename":"Prot_000.pdf","size":545533},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-08-15","uploadDate":"2020-02-10T07:26","filename":"SAP_001.pdf","size":399545}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000078784","term":"Vortioxetine"},{"id":"D005473","term":"Fluoxetine"}],"ancestors":[{"id":"D010879","term":"Piperazines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D011437","term":"Propylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}